Le Lézard
Classified in: Health, Business
Subjects: LIC, FDA

Water Street's Partnership with Leading Medical Products Company Leads to FDA Approval of First Presentation of Bivalirudin in Frozen Premixed Ready-to-Use Formulation


CHICAGO, Jan. 22, 2018 /PRNewswire/ -- Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry, announced today that its development partnership with a leading medical products company has resulted in the U.S. Food and Drug Administration (FDA) approval of cardiovascular medication Bivalirudin in 0.9 percent Sodium Chloride Injection (bivalirudin). It is the first presentation of bivalirudin in a frozen, premixed, ready-to-use formulation.

The approval of bivalirudin marks the fifth drug product successfully developed by Water Street's company, Celerity Pharmaceuticals, LLC. Celerity both funded and led the development and approval of bivalirudin through its strategic partnership with the medical products company. Following FDA approval of bivalirudin, Celerity transferred ownership to its partner, which will commercially launch the new product in the United States.

"We are honored that our partner entrusted us to develop this new presentation of bivalirudin ? the first in the United States and the only available in a frozen premixed solution," said Al Heller, operating partner with Water Street and chairman of Celerity. "We look forward to continuing to work together to advance our partner's goal of engaging its innovative technologies with medicines that help simplify drug preparation and help bolster clinician efficiency."

About Water Street

Water Street is a strategic investor focused exclusively on health care. The firm has a strong record of building market-leading companies across key growth sectors in health care. It has worked with some of the world's leading health care companies on its investments including Johnson & Johnson, Medtronic, Smith & Nephew and Walgreen Co. Water Street's team is comprised of industry executives and investment professionals with decades of experience investing in and operating global health care businesses. The firm is headquartered in Chicago. For more information about Water Street, visit waterstreet.com.

 

SOURCE Water Street Healthcare Partners


These press releases may also interest you

at 11:15
Variantyx, a leader in molecular diagnostics, announced today that it has secured an additional $36 million in funding from its portfolio of investors which includes Peregrine Ventures, Pitango HealthTech, New Era Capital Partners and Bosch Ventures....

at 11:03
The heart of Vajra Coffee's natural decaffeination process lies in its adoption of the Swiss Water® Process, a natural method that removes 99% of caffeine...

at 11:00
United Imaging Healthcare (SSE:688271) has published its 2023 Environment, Social, and Governance (ESG) Report, reaffirming its mission to bring Equal Healthcare for All. This report highlights the company's advancements in corporate responsibility,...

at 11:00
United Imaging Healthcare (SSE:688271), a global leader in manufacturing advanced medical imaging and radiotherapy equipment, has released their 2023 annual report. The report reveals that the company achieved 11.41 billion CNY in revenue in 2023,...

at 10:54
Pierre Fabre Laboratories announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of OBGEMSAtm (vibegron under the international...

at 10:49
Sustain Exchange LLC is proud to announce a partnership with HearMe, a leading behavioral health peer support platform focused on ensuring healthy lives and promoting well-being. As part of this innovative partnership, SustainAble Exchange will...



News published on and distributed by: